Hydrogen Sulfide Inhibits Human Platelet Aggregation In Vitro in Part by Interfering Gap Junction Channels: Effects of ACS14, a Hydrogen Sulfide-releasing Aspirin

Heart Lung and Circulation

Volumn 24, Issue 1, 2015, Pages 77-85

  Gao, Lin ^a   Cheng, Chun ^a   Sparatore, Anna ^b   Zhang, Huili ^a   Wang, Changqian ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

ACS14; Aspirin; Gap junction; Hydrogen sulfide; Platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; ADENOSINE DIPHOSPHATE; ALPHA2B BETA3 INTEGRIN; HYDROGEN SULFIDE; HYDROGEN SULFIDE RELEASING ASPIRIN; INTEGRIN; PADGEM PROTEIN; ROTIGAPTIDE; THROMBIN; UNCLASSIFIED DRUG; 2-ACETYLOXYBENZOIC ACID 4-(3-THIOXO-3H-1,2-DITHIOL-5-YL)PHENYL ESTER; ANTITHROMBOCYTIC AGENT; DISULFIDE; GASOTRANSMITTER;

ADULT; ARTICLE; CELL COMMUNICATION; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; NORMAL HUMAN; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; ANALOGS AND DERIVATIVES; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GAP JUNCTION; MALE; METABOLISM; THROMBOCYTE;

ADULT; ASPIRIN; BLOOD PLATELETS; DISULFIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GAP JUNCTIONS; GASOTRANSMITTERS; HUMANS; HYDROGEN SULFIDE; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 84919639708     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2014.05.019     Document Type: Article

References (27)

1. Renga B. Hydrogen sulfide generation in mammals: the molecular biology of cystathionine-β-synthase (CBS) and cystathionine-γ-lyase (CSE). Inflamm Allergy Drug Targets 2011, 10:85-91.
2. Lefer D.J. A new gaseous signaling molecule emerges: cardioprotective role of hydrogen sulfide. Proc Natl Acad Sci 2007, 104:17907-17908.
3. 2S). Cell Biochem Funct 2010, 28:95-106.
4. Zagli G., Patacchini R., Trevisani M., Abbate R., Cinotti S., Gensini G.F., et al. Hydrogen sulfide inhibits human platelet aggregation. Eur J Pharmacol 2007, 559:65-68.
5. Rossoni G., Manfredi B., Tazzari V., Sparatore A., Trivulzio S., Del Soldato P., et al. Activity of a new hydrogen sulfide-releasing aspirin (ACS14) on pathological cardiovascular alterations induced by glutathione depletion in rats. Eur J Pharmacol 2010, 648:139-145.
6. Pircher J., Fochler F., Czermak T., Mannell H., Kraemer B.F., Wörnle M., et al. Hydrogen sulfide-releasing aspirin derivative ACS14 exerts strong antithrombotic effects in vitro and in vivo. Arterioscler Thromb Vasc Biol 2012, 32:2884-2891.
7. Grambow E, Mueller-Graf F, Delyagina E, Frank M, Kuhla A, Vollmar B. Effect of the hydrogen sulfide donor GYY4137 on platelet activation and microvascular thrombus formation in mice. Platelets 2013, in press.
8. Saez J.C., Berthoud V.M., Branes M.C., Martinez A.D., Beyer E.C. Plasma membrane channels formed by connexins: their regulation and functions. Physiol Rev 2003, 83:1359-1400.
9. Martin P.E., Evans W.H. Incorporation of connexins into plasma membranes and gap junctions. Cardiovasc Res 2004, 62:378-387.
10. Figueroa X.F., Duling B.R. Gap junctions in the control of vascular function. Antioxid Redox Signal 2009, 11:251-266.
11. Rohr S. Role of gap junctions in the propagation of the cardiac action potential. Cardiovasc Res. 2004, 62:309-322.
12. Bruzzone R.D.R. Structure and functions of gap junctions in the developing brain. Cell Tissue Res 2006, 326:239-248.
13. Kidder G.M., Mhawi A.A. Gap junctions and ovarian folliculogenesis. Reproduction 2002, 123:613-620.
14. Dorshkind K., Green L., Godwin A., Fletcher W.H. Connexin-43-type gap junctions mediate communication between bone marrow stromal cells. Blood 1993, 82:38-45.
15. Vaiyapuri S., Jones C.I., Sasikumar P., Moraes L.A., Munger S.J., Wright J.R., et al. Gap junctions and connexin hemichannels underpin hemostasis and thrombosis. Circulation 2012, 125:2479-2491.
16. Angelillo-Scherrer A., Fontana P., Burnier L., Roth I., Sugamele R., Brisset A., et al. Connexin37 limits thrombus propensity by downregulating platelet reactivity. Circulation 2011, 124:930-939.
17. Meens M.J., Pfenniger A., Kwak B.R. Risky communication in atherosclerosis and thrombus formation. Swiss Med Wkly 2012, 142:w13553.
18. Lin X., Zemlin C., Hennan J.K., Petersen J.S., Veenstra R.D. Enhancement of ventricular gap-junction coupling by rotigaptide. Cardiovasc Res 2008, 79:416-426.
19. Shiroshita-Takeshita A., Sakabe M., Haugan K., Hennan J., Nattel S. Model- Dependent Effects of the Gap Junction Conduction-Enhancing Antiarrhythmic Peptide Rotigaptide (ZP123) on Experimental Atrial Fibrillation in Dogs. Circulation 2007, 115:310-318.
20. Fuster V., Dyken M.L., Vacans P.S., Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 1993, 87:659-675.
21. Wallace J.L., Caliendo G., Santagada V., Cirino G., Fiorucci S. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 2007, 132:261-271.
22. Zhang H., Guo C., Zhang A., Fan Y., Gu T., Wu D., et al. Effect of S-aspirin, a novel hydrogen-sulfide-releasing aspirin (ACS14), on atherosclerosis in apoE-deficient mice. Eur J Pharmacol 2012, 697:106-116.
23. Patrono C., García Rodríguez L.A., Landolfi R., Baigent C. Low dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005, 353:2373-2383.
24. Sparatore A., Perrino E., Tazzari V., Giustarini D., Rossi R., Rossoni G., et al. Pharmacological profile of a novel H(2)S-releasing aspirin. Free Radic Biol Med 2009, 46:586-592.
25. Andrews R.K., Berndt M.C. Platelet physiology and thrombosis. Thromb Res 2004, 114:447-453.
26. Zhang H., Zhang A., Guo C., Shi C., Zhang Y., Liu Q., et al. S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodeling. PLoS One 2011, 6:e26441.
27. Morel A., Malinowska J., Olas B. Antioxidative properties of hydrogen sulfide may involve in its antiadhesive action on blood platelets. Clin Biochem 2012, 45:1678-1682.